title: Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
abstract: A 1-year prospective, open, randomized, controlled trial was conducted as a pilot study to examine the effect of intermittent administration of 200 IU intranasal salmon calcitonin and 1alpha(OH) vitamin D3 [1alpha(OH)D3] on bone mineral density (BMD) of the lumbar spine and hip as well as on the markers of bone metabolism in women with postmenopausal osteoporosis. A total of 102 randomly recruited women received either 200 IU intranasal salmon calcitonin (Miacalcic nasal 200, Novartis, Basel, Switzerland) daily, 1 month on-1 month off, 0.25 mug 1alpha(OH)D3, and 500 mg elemental calcium continuously (n=57 women) or only 0.25 mug 1alpha(OH)D3 and 500 mg calcium (n=45 women) for a period of 1 year. BMD of the lumbar spine and hip plus biochemical markers reflecting calcium (Ca) metabolism and bone turnover [serum Ca, serum phosphorus, intact parathormone (iPTH), total and bone-specific alkaline phosphatase, osteocalcin levels, 24-h urinary Ca, morning fasting urinary Ca/creatinine, and Pyrilinks-D/creatinine ratio] were measured at the beginning of the study before treatment and after 6 and 12 months of treatment. Baseline characteristics of participants, including age, body mass index, lumbar and hip BMD, and biochemical markers were similar between the two groups. A total of 91 patients completed the study (50 in the salmon calcitonin nasal spray group and 41 in the other group). Lumbar BMD increased significantly in the salmon calcitonin group from baseline (3.0%, p=0.005) and in comparison to the non-calcitonin-treated group (p=0.009). The salmon calcitonin group also had a significant increase in femoral neck BMD compared with baseline values (3.1%, p=0.0005) and in comparison to the non-calcitonin-treated group (p=0.0005) in Ward's triangle BMD (2.9% from baseline values, p=0.009) and in comparison to the non-calcitonin-treated group (p=0.005) in trochanteric BMD (3.4% from baseline values, p=0.007) and in comparison to the non-calcitonin-treated group (P=0.01). Urinary Ca/creatinine and Pyrilinks-D/creatinine levels were significantly decreased from baseline in the salmon calcitonin-treated group (-6.1 and -6.3%, respectively, p=0.001). Bone-specific alkaline phosphatase levels were also significantly decreased from baseline in the salmon calcitonin-treated group (-3.6%, p=0.003). In the same group, a significant decrease in iPTH serum levels compared to baseline values (-2.5%, p=0.005) and in comparison to the non-calcitonin-treated group (p=0.005) was noted. In conclusion, in this pilot study, 1-year intermittent treatment with 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH)D3 produced a significant effect on bone turnover and BMD in postmenopausal women with osteoporosis.
authors.affiliation: Laboratory for the Research of the Musculoskeletal System (LRMS), KAT Hospital, Kifisia, Greece. lyritis@lrms.edu.gr
authors.forename: Evangelia
authors.initials: E
authors.lastname: Kaskani
authors.forename: G P
authors.initials: GP
authors.lastname: Lyritis
authors.forename: C
authors.initials: C
authors.lastname: Kosmidis
authors.forename: A
authors.initials: A
authors.lastname: Galanos
authors.forename: G
authors.initials: G
authors.lastname: Andypas
authors.forename: K
authors.initials: K
authors.lastname: Chorianopoulos
authors.forename: A
authors.initials: A
authors.lastname: Giagiosis
authors.forename: K
authors.initials: K
authors.lastname: Iliadou
authors.forename: A
authors.initials: A
authors.lastname: Karagianis
authors.forename: K
authors.initials: K
authors.lastname: Katsimichas
authors.forename: A
authors.initials: A
authors.lastname: Koskinas
authors.forename: K
authors.initials: K
authors.lastname: Matsouka
mesh_terms: D015502:Absorptiometry, Photon; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000281:Administration, Intranasal; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood / Q000652:urine; D015519:Bone Density / Q000187:drug effects*; D002116:Calcitonin / Q000008:administration & dosage* / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism*; D003404:Creatinine / Q000097:blood / Q000652:urine; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage* / Q000627:therapeutic use; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging*; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D010384:Pelvic Bones / Q000000981:diagnostic imaging*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D000700:Analgesics; D015415:Biomarkers; D006887:Hydroxycholecalciferols; D015675:Osteocalcin; C028815:salmon calcitonin; D002116:Calcitonin; D003404:Creatinine; D000469:Alkaline Phosphatase; D002118:Calcium; C008088:alfacalcidol